Synopsis

Source of validity: Scientific
Rating (out of 5): 2

S-adenosyl-L-methionine (SAMe) has been investigated for its potential role in supporting patients with Parkinson’s Disease (PD), though the evidence is limited and primarily preliminary. SAMe is a naturally occurring compound involved in methylation reactions and the synthesis of neurotransmitters such as dopamine, which is notably deficient in PD. Early scientific interest arose from observations that SAMe levels may be altered in PD patients, and that methylation processes could influence the metabolism of levodopa, a standard PD medication. Some small clinical studies have explored SAMe as an adjunct to levodopa therapy, suggesting that it might help improve depressive symptoms frequently experienced by PD patients, likely due to its antidepressant properties rather than a direct effect on motor symptoms. However, there is little robust evidence from large, high-quality randomized controlled trials demonstrating a significant benefit of SAMe on the core motor symptoms of PD. Most research focuses on its use for depressive symptoms in PD, where results have been modest but promising. Safety concerns also exist, as SAMe may increase homocysteine levels, potentially exacerbating cardiovascular risk, which is already elevated in PD patients. Overall, while there is a scientific basis for investigating SAMe in PD, the current evidence is weak and not sufficient to recommend routine use for treating Parkinson’s Disease itself, though it may have a role in managing comorbid depression.

More about SAMe (S-adenosyl-L-methionine disulfate p-toluensulfate)
More about Parkinson's Disease

Other ingredients used for Parkinson's Disease

Other health conditions supported by SAMe (S-adenosyl-L-methionine disulfate p-toluensulfate)

Products containing SAMe (S-adenosyl-L-methionine disulfate p-toluensulfate)

Metagenics Blisphora®
Douglas Laboratories SAM-e
Designs For Health SAMe
Designs For Health SAMe
Pure Encapsulations SAMe (S-Adenosylmethionine)